Pharming Group Reports Strong Preliminary Financial Results for 2018 including first year of net profit
RUCONEST® (conestat alfa)
RUCONEST® (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of angioedema attacks in patients with HAE
View our financial calendar and what conferences, meetings and congresses we will visit in 2019 on our upcoming events page.
Our innovative technology and processes are aimed at purification and formulation of recombinant products. We are continuously looking for highly talented and motivated individuals to join our team.